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depression and anxiety medication use, and lower health 
and disability status were significantly associated with medi-
cal cannabis use. In the multivariate analysis, final model, 
household income, alcohol use, and disability levels were as-
sociated with medical cannabis use.  Conclusions/Scientific 
Significance:  Compared to RCUs, medical users appear to be 
mainly  characterized by factors negatively influencing their 
overall health status. Future studies should investigate the 
actual impact and net benefits of medical cannabis use on 
these health  problems.  © 2017 S. Karger AG, Basel 
 Introduction 
 Cannabis is the most commonly used illegal drug glob-
ally, and current (e.g., “past year”) use rates (about 8–14% 
among adults, and 21–25% among adolescents) are com-
paratively high in Canada, and particularly in Ontario  [1, 
2] . Recently, control regimes for cannabis as a psychoac-
tive substance have diversified considerably in North 
American jurisdictions, from mainly prohibitive to more 
liberal control systems, including legal regimes, where 
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 Abstract 
 Background: While recreational cannabis use is common, 
medical cannabis programs have proliferated across North 
America, including a federal program in Canada. Few com-
parisons of medical and recreational cannabis users (RCUs) 
exist; this study compared these groups on key characteris-
tics.  Methods: Data came from a community-recruited sam-
ple of formally approved medical cannabis users (MCUs;  n = 
53), and a sub-sample of recreational cannabis users (RCUs; 
 n = 169) from a representative adult survey in Ontario (Can-
ada). Samples were telephone-surveyed on identical mea-
sures, including select socio-demographic, substance and 
medication use, and health and disability measures. Based 
on initial bivariate comparisons, multivariate logistical re-
gression with a progressive adjustment approach was per-
formed to assess independent predictors of group status.  Re-
sults: In bivariate analyses, older age, lower household in-
come, lower alcohol use, higher cocaine, prescription opioid, 
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cannabis is legally accessible for therapeutic purposes  [3, 
4] . Therapeutic benefits from cannabis have been sug-
gested for numerous, usually chronic, health conditions, 
yet are most strongly evidenced primarily for neuropath-
ic pain, spasticity, as well as anti-emetic and appetite-
stimulant effects (e.g., for “wasting syndrome”)  [5–8] . 
Medical cannabis control regimes exist in numerous US 
states and Canada (since 2001), among other countries  [3, 
4, 9] . Through iterative revisions to the medical cannabis 
program in Canada (e.g., the Access to Cannabis for Med-
ical Purposes Regulations 2016), access has been consid-
erably simplified, and under current regulations, medical 
cannabis use can be endorsed by a physician for virtually 
any health condition where benefits are expected; by 2015 
>50,000 individuals were estimated to be enrolled in the 
program  [9, 10] .
 A worthwhile question is whether medical cannabis 
users (MCUs) differ from non-medical (or recreational) 
cannabis users on key characteristics (e.g., socio-demo-
graphics, substance use, or health indicators). One could 
expect numerous differences, as MCU populations report 
several chronic/severe health conditions (e.g., chronic 
pain, HIV/AIDS, arthritis, sleep and mental health issues) 
for which therapeutic use is sought  [11–14] . Additionally, 
data suggest that medical use of cannabis may act as a 
substitute for other psychoactive substances or medica-
tions (e.g., alcohol, psychotropic drugs)  [11, 12, 15, 16] . 
This might be in contrast to recreational use, where can-
nabis use commonly co-occurs with other substance use, 
or – especially among intensive/problematic users – with 
substance use disorders or co-morbid (e.g., mental) health 
problems  [17–20] . Conversely, the dividing lines between 
“medical” and “recreational” cannabis use may be fluid 
and unclear. Up to 1 in 4 cannabis users in Canada have 
self-reported their cannabis use to include medical rea-
sons  [10, 21] . In the context of persistent prohibition con-
trol, medical cannabis regimes may have offered a “side-
door” legal access for many users who may otherwise 
consider their use as recreational  [9] .
 Few empirical comparisons between medical and rec-
reational cannabis users (RCUs) exist; specifically, two 
recent US studies found few differences: they generally 
observed that medical users had more medical problems, 
including pain, yet lower alcohol and drug use severity 
compared to recreational users  [22, 23] . However, no 
 Canadian studies exist, although both the characteristics 
of MCUs, as well as the particular contexts of medical 
cannabis use regimes and the health care system in 
 Canada, may make for distinct results, and so relevantly 
contribute to this emerging area of knowledge. On this 
basis, we seized upon the unique opportunity of identi-
cally assessed (formally authorized) medical cannabis 
and RCU samples in Canada for the present study, which 
compared these two groups in terms of socio-demo-
graphic, substance and medication use, and health and 
disability measures.
 Methods 
 The data analyzed in this study were drawn from an Ontario-
based community-recruited sample of formally approved MCUs, 
and a sub-sample of current RCUs identified in the CAMH Mon-
itor (CM), the long-standing representative telephone-based sur-
vey of the Ontario general adult (18+ years) population, focusing 
on socio-demographic, substance use and health/disability mea-
sures  [24] . While recruited differently, both samples were assessed 
by the CM protocol based on identical methods and questions.
 MCU Sample 
 The MCU sample was assembled using a community-based re-
cruitment approach across Ontario between June and August 
2015. Study information was circulated in medical cannabis dis-
pensaries, information points, and posted on relevant websites us-
ing print and virtual information tools; study applicants called a 
central study number and were assessed for study eligibility. Cri-
teria included 18 years of age or older; resident of Ontario; and 
holding formal approval under federal regulations for medical 
cannabis use (e.g., the initial Marihuana Medical Access Regula-
tions or subsequent Marihuana for Medical Purposes Regula-
tions). Of the 97 individuals screened, 86 were eligible and 55 pro-
vided consent and were enrolled into the study. Participants were 
contacted over the telephone by the Institute for Social Research, 
Toronto, and 53 completed the CM survey protocol  [24] .
 RCU Sample 
 The RCU sample was selected from a random subsample ( n = 
510) of the 2015 cycle of the CM survey. Those respondents who 
had indicated any “cannabis use in the past 12 months” ( n = 122) 
were selected and the sample was weighted to adjust for varying 
selection probabilities and regional representation, resulting in an 
RCU sample of 169.
 Measures 
 Select CM survey measures administered to both samples were 
examined in the present analyses, including socio-demographic 
factors like gender, age, and household income. Substance and 
medication use variables including tobacco smoking (past 12 
months); alcohol use (past 12 months); hazardous alcohol use 
measured using the Alcohol Use Disorders Identification Test, a 
10-item screening tool (with a cutoff score of >7 indicating hazard-
ous use)  [25] ; cocaine use (lifetime); any (medical and non-medi-
cal) prescription opioid use; and prescription depression and anx-
iety medication use; furthermore, cannabis use frequency (i.e., 
daily or near-daily use in last 3 months) was examined for sample 
descriptions. Health and disability measures such as self-rated 
health, dichotomized into “excellent, very good, or good” and “fair 
or poor”  [26, 27] ; number of physically unhealthy or mental dis-
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tress days (past 30 days; dichotomized into “0–13 days” and “14+ 
days”); the 12-item version of the World Health Organization Dis-
ability  Assessment Schedule 2.0 (WHODAS) measuring disability 
in six major life domains, with summary scores from 0 (no disabil-
ity) to 100 (full disability); scores were trichotomized per normed 
standards into 0–9; 10–16; 17–100  [28] .
 Statistical Analysis 
 For analysis, the MCU and RCU samples were merged, provid-
ing an unweighted sample size of 175 participants, and a final anal-
ysis sample of 222 (after weighting) on which the analyses are 
based. Covariate selection for the multivariate analyses was based 
on theoretical models and existing evidence. Bivariate odds ratio 
(OR) (including 95% confidence intervals [CIs]) analyses were 
performed to identify variables associated with the cannabis user 
group status. Then, multivariate logistical regression models were 
computed using a progressive adjustment approach with succes-
sive entry of variable blocks. The first block included socio-demo-
graphic factors, followed by substance and medication use vari-
ables, and finally health and disability measures (see models 1, 2 
and 3 of  Table 2 ). At each stage of analysis, the variables signifi-
cantly related to group status were carried over to the next stage. 
To assess the goodness-of-fit of the regression models at each 
stage, the generalized (pseudo) (R 2 ) values and “Hosmer-Leme-
show tests” were computed  [29] . All analyses were weighted and 
performed using SAS version 9.3.
 Consent and Ethics Approval 
 Written consent was obtained from MCUs; RCU respondents 
provided verbal consent during CM survey participation. Study 
procedures were approved by the CAMH Research Ethics Board 
(references 305/2009-06 and 17/2015-01).
 Results 
 The vast majority (84.9%) of the MCU group and only 
a small minority (9.8%) of the RCU group used cannabis 
on a daily/near-daily basis ( p < 0.0001).
 Results of the bivariate study variable comparisons be-
tween the MCU and RCU groups are presented in  Ta-
ble 1 . Approximately two-thirds of the sample were male 
in both groups; the RCU sample had a higher income lev-
el and was younger. Lifetime cocaine use, prescription 
opioid use, and depression and anxiety medication use 
were all more common in the MCU sample; conversely, 
current and hazardous alcohol use was more common in 
the RCU sample. Compromised health and disability sta-
tus – specifically, fair/poor health, physically unhealthy 
days, mental distress days and elevated WHODAS dis-
ability scores – were all more common in the MCU group.
 Multivariate regression analyses results are presented 
in  Table 2 . In the final model, lower household income, 
lower alcohol use, and higher WHODAS disability scores 
emerged as significant predictors of MCU status; high 
WHODAS disability scores (17–100) increased the odds 
of MCU status by almost 10 times (OR 9.98; 95% CI 3.05–
32.68) relative to low scores (0–9). The amount of vari-
ance explained by the set of variables included at each 
stage increased to 58% in model 3; the model-fit-statistic 
also indicated model 3 as the best fit for the observed data.
 Discussion 
 Our analyses compared medical and RCU samples in 
Ontario, Canada, assessed by identical methods and mea-
sures. These data contribute to the currently limited evi-
dence comparing these cannabis user groups in the con-
text of increasing medical cannabis utilization in North 
America  [22, 23] , providing a unique Canadian perspec-
tive. That perspective is unique, in that no such compari-
sons have existed for Canada to date, and also given the 
distinct features of medical cannabis availability and its 
use in Canada. Such availability has existed by way of na-
tional regulations since 2001, which have gradually been 
eased and allowed increasingly large numbers of people 
access to medical cannabis use based on increasingly flex-
ible requirements.
 The two study groups were associated with distinctly 
different cannabis use patterns, in that close to all (4 in 5) 
of the MCU group, and yet only 1 in 10 of the RCU group, 
featured frequent (i.e., daily or near-daily) cannabis users. 
These differences in use patterns are to be expected, given 
the distinct user group status and the presumed respec-
tive reasons (i.e., medical versus recreational) for use. In 
terms of differences in group co-variates based on the 
multivariate analysis results, the MCU group reported 
higher disability scores after controlling for potential 
confounders. This likely reflects the fact that MCUs com-
monly feature severe overall health problems, as docu-
mented by several North American studies  [13, 30–32] , 
including (often multiple) chronic physical and/or men-
tal conditions. These chronic conditions are often indi-
cated as the reason for medical cannabis use. The signifi-
cant inter-group differences in disability levels were fur-
ther corroborated by other health indicators (e.g., 
self-rated health, physically or mentally unhealthy days), 
where the MCU group consistently reported more com-
promised status in bivariate analyses.
 The MCU group was characterized by less common al-
cohol consumption than the RCU group (as well as less 
common hazardous alcohol use, which defined almost 
half of the RCU group). This finding is consistent with 
comparably low alcohol use found in other MCU samples 
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Table 1.  Demographic, substance and drug use, and health status characteristics of medical and recreational cannabis users and bivari-
ate analysis results (n = 222)
Variables Total, 
n (%)
Medical,
n (%)
Recreational,
n (%)
OR (95% CI)*
Gender
Male 147 (66.4) 37 (69.8) 110 (65.5) 1.22 (0.63–2.39)
Female 74 (33.6) 16 (30.2) 58 (34.5) Ref.
Age, years
18–34 107 (48.2) 12 (22.6) 95 (56.2) 0.35 (0.14–0.87)
35–54 74 (33.2) 30 (56.6) 44 (26.0) 1.89 (0.82–4.35)
55+ 41.3 (18.6) 11 (20.8) 30 (17.8) Ref.
Household income, CAD ($)
80,000+ 93 (49.8) 15 (28.3) 78 (46.2) 0.07 (0.03–0.19)
50,000–79,000 41 (21.9) 9 (17.0) 32 (18.9) 0.11 (0.04–0.32)
30,000–49,000 24 (12.8) 7 (13.2) 17 (10.1) 0.16 (0.05–0.52)
<30,000 29 (15.5) 21 (39.6) 8 (4.7) Ref.
Tobacco smoking&&
Yes 81 (36.6) 19 (35.8) 62 (36.9) 0.96 (0.50–1.80)
No 141 (63.4) 34 (64.2) 107 (63.1) Ref.
Alcohol use&&
Yes 200 (90.2) 38 (71.7) 162 (96.1) 0.10 (0.04–0.27)
No 21 (9.7) 15 (28.3) 7 (3.9) Ref.
Hazardous alcohol use
AUDIT score >8 83 (37.8) 10 (18.9) 73 (44.0) 0.30 (0.14–0.63)
AUDIT score ≤8 136 (62.2) 43 (81.1) 93 (56.0) Ref.
Cocaine use&
Yes 97 (44) 32 (60.4) 65 (38.8) 2.40 (1.28–4.52)
No 123 (56) 21 (39.6) 102 (61.2) Ref.
Any prescription opioid use&&
Yes 75 (33.9) 27 (50.9) 48 (28.5) 2.61 (1.38–4.91)
No 147 (66.1) 26 (49.1) 121 (71.5) Ref.
Depression medication use&&
Yes 48 (21.8) 18 (34.0) 30 (18) 2.34 (1.17–4.67)
No 173 (78.2) 35 (66.0) 138 (82) Ref.
Anxiety medication use
Yes 48 (21.8) 20 (37.7) 28 (16.8) 3.00 (1.51–5.97)
No 173 (78,2) 33 (62.3) 140 (83.2) Ref.
Self-rated health
Fair or poor 38 (17.2) 16 (30.2) 22 (13) 2.89 (1.38–6.04)
Good, excellent 184 (82.8) 37 (69.8) 146 (87) Ref.
Number of physically unhealthy days&&&
14+ days 34 (15.3) 16 (30.2) 18 (10.6) 3.66 (1.70–7.88)
0–13 days 186 (84.7) 37 (69.8) 149 (89.4) Ref.
Number of mental distress days&&&
14+ days 46 (20.7) 16 (30.2) 30 (17.7) 2.01 (1.00–4.08)
0–13 days 175 (79.3) 37 (69.8) 138 (82.3) Ref.
WHODAS score (0–100)
17–100 48 (21.5) 30 (56.6) 18 (10.5) 13.30 (6.00–29.48)
10–16 41 (18.7) 8 (15.1) 33 (19.8) 1.88 (0.73–4.80)
0–9 132 (59.8) 15 (28.3) 118 (69.7) Ref.
 All frequencies are weighted and rounded to the nearest integer.* ORs represent risk of medical versus recreational cannabis use.& In lifetime; && in past 12 months; &&& in last 30 days.
AUDIT, Alcohol Use Disorders Identification Test; WHODAS, World Health Organization Disability Assessment Schedule 2.0.
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Table 2.  Regression models of factors predicting medical versus recreational cannabis user group status (n = 222)
Variables  OR (95% CI)*
model 1 model 2 model 3
Gender
Male 0.83 (0.38–1.82) 0.81 (0.32–2.02) 1.37 (0.50–3.78)
Female Ref. Ref. Ref.
Age, years
18–34 0.32 (0.11–0.90) 0.58 (0.16–2.11) 0.65 (0.17–2.57)
35–54 1.84 (0.70–4.82) 3.33 (1.01–11.02) 3.06 (0.85–11.02)
55+ Ref. Ref. Ref.
Household income, CAD ($)
80,000+ 0.07 (0.02–0.19) 0.06 (0.02–0.25) 0.09 (0.02–0.31)
50,000–79,000 0.11 (0.03–0.35) 0.10 (0.02–0.43) 0.14 (0.03–0.65)
30,000–49,000 0.20 (0.05–0.72) 0.23 (0.05–1.04) 0.26 (0.05–1.29)
<30,000 Ref. Ref. Ref.
Tobacco smoking&&
Yes 0.58 (0.23–1.47)
No Ref.
Alcohol use&&
Yes 0.19 (0.05–0.75) 0.17 (0.04–0.69)
No Ref. Ref. 
Hazardous alcohol use
AUDIT score >8 0.57 (0.20–1.61)
AUDIT score ≤8 Ref.
Cocaine use&
Yes 1.60 (0.66–3.88)
No Ref.
Any prescription opioid use&&
Yes 1.58 (0.67–3.71)
No Ref.
Depression medication use&&
Yes 2.39 (0.58–9.85)
No Ref.
Anxiety medication use
Yes 1.88 (0.51–6.99)
No Ref.
Self-rated health
Fair or poor 0.35 (0.09–1.46)
Good, excellent Ref.
Number of physically unhealthy days&&&
14+ days 2.78 (0.46–6.98)
0–13 days Ref.
Number of mental distress days&&&
14+ days 1.92 (0.60–6.17)
0–13 days Ref.
WHODAS score (0–100)
17–100 9.98 (3.05–32.68)
10–16 1.07 (0.32–3.53)
0–9 Ref.
Generalized R2 0.41 0.54 0.58
Hosmer–Lemeshow goodness-of-fit (p values) 0.03 <0.001 0.003
 All frequencies are weighted and rounded to the nearest integer.* ORs represent risk of medical versus recreational cannabis use.& In lifetime; && in past 12 months; &&& in last 30 days.
AUDIT, Alcohol Use Disorders Identification Test; WHODAS, World Health Organization Disability Assessment Schedule 2.0.
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 [16, 22, 23] , as well as the fact that alcohol use commonly 
co-occurs with recreational cannabis use  [33] . This result 
may also lend indirect support to the suggestion – also 
considering other self-report data from MCUs – that med-
ical cannabis use may reduce (by “substitution”) certain 
psychoactive substance use, including alcohol  [11, 12, 34] . 
Notably, our multivariate analyses did not identify inter-
group differences with regard to psychoactive substance 
or medications use, even though these had emerged in the 
bivariate analyses. There, key psychotropic medications 
use (i.e., opioid, depression and anxiety medications), but 
also a lifetime history of cocaine use were found to be more 
common among the MCU sample. While the former may 
be intuitive due to the MCU group’s elevated physical and 
mental health burden, the latter seems to be a counterin-
tuitive finding which cannot be readily explained.
 While the multivariate analysis did not confirm sig-
nificant differences in gender or age, it indicated for the 
MCU group to be characterized by significantly lower 
household income. This is likely indicative of recreation-
al cannabis use being spread more across socio-economic 
strata, but also – as possibly influenced by the much high-
er levels of health problems and disability – that a large 
proportion of individuals in the MCU group were likely 
not generating income from employment, and/or lived on 
limited social (e.g., disability, welfare) benefits/payments.
 This study includes important potential limitations. 
The MCU sample consisted of a small, community-re-
cruited convenience sample, involving possible sampling 
bias with possible overrepresentation of certain charac-
teristics (e.g., health problems or disability). The MCU 
sample size was also relatively small, rendering limited 
statistical power. While the general CM sample (from 
which the RCU sample was drawn) was considered rep-
resentative of the Ontario adult population, the CM sur-
vey had a limited response rate (45%)  [24] and excluded 
certain marginalized populations. On this basis, compar-
ison results are not generalizable beyond the specific 
study samples or the Ontario-specific study context. In 
addition, the survey instruments relied on self-report 
items, which may entail response bias.
 In sum, our study shed some light on comparative char-
acteristics between MCUs and RCUs in a Canadian con-
text. The differences found are limited to select markers 
(similar to those found by other studies), most of which 
presumably related to elevated chronic disease status 
among medical users. Further, the findings can be inter-
preted in two different ways; either, the outcomes of the 
current Canadian medical cannabis program are success-
fully reaching its intended audience (e.g., users who suffer 
from worse disability/health status), or alternatively, the 
program is being utilized by people who are potentially not 
using cannabis strictly for medical uses. These specific dy-
namics are important and should be examined more close-
ly as one of the research questions arising from the present 
study. For purposes of future policy-making in this con-
tentious realm, it will be important to further rigorously 
(e.g., based on large and representative samples) examine 
the potential differences in characteristics and outcomes 
between these two coexistent cannabis user groups.
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